The benefits and acceptability of virtual reality interventions for women with metastatic breast cancer in their homes; a pilot randomised trial

Lisa M. Reynolds1*, Alana Cavadino2, Stanley Chin1, Zoë Little3, Amelia Akroyd1, Geraldine Tennant1, Rosie Dobson4, Reuben Broom5 and Adèle Gautier6

Abstract

Background: Women with metastatic breast cancer (MBC) report debilitating physical and psychological symptoms, including fatigue, anxiety, and pain, that greatly impact their quality of life. Immersive virtual reality (VR) has been proposed as an adjunctive pain therapy for patients with cancer, and evidence suggests it may also decrease symptoms of anxiety and depression. The purpose of this pilot study was to assess whether VR should be pursued as a feasible and acceptable adjunctive therapy to alleviate physical and psychological symptoms in women with MBC.

Methods: We conducted a pilot study testing the acceptability and efficacy of VR interventions with MBC patients to improve quality of life and to produce enduring decreases in fatigue, pain, depression, anxiety, and stress. Participants completed two different week-long VR experiences, reporting the prevalence of symptoms immediately before and after each study week, and 48 h later. Linear mixed models including fixed effects (VR intervention, counterbalancing order, and study week) and random effects (participant) were used to assess the effect of immersive VR on all outcome measures.

Results: Thirty-eight women with MBC completed the VR interventions and were included in analyses. Significant improvements post-intervention and/or 48 h later were demonstrated for quality of life, fatigue, pain, depression, anxiety, and stress. Across the entire study period, these differences met the criteria of a clinically important difference for quality of life, fatigue, depression, and stress. Participants reported feelings of relaxation and enjoyment and were highly likely to use the interventions again.

Conclusions: Our results demonstrate that VR experiences offer enduring benefits to the physical and psychological well-being of women with MBC. VR interventions are a feasible and acceptable intervention that can be conducted in a patient’s own home. Such interventions are worthy of future investigation as a novel approach to improving quality of life in a patient population that have often been overlooked.

Trial registration: Prospectively registered on 25th October 2019 with Australian New Zealand Clinical Trials Registry (ref: ACTRN12619001480178).

*Correspondence: l.reynolds@auckland.ac.nz
1 Department of Psychological Medicine, The University of Auckland, Auckland, New Zealand

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Metastatic Breast Cancer (MBC) can present de novo (5–10% of all breast cancer diagnoses), or as a recurrence after early breast cancer (20–30% of patients will experience a recurrence) [1]. MBC is essentially incurable and treatment for patients focuses on prolonging survival and preserving quality of life [2]. People living with MBC commonly report experiencing debilitating symptoms from both the cancer itself and its treatments [3]. Symptoms are both physical (e.g., pain, fatigue [4]) and psychological (e.g., depression, anxiety [5]) and can significantly impact quality of life and be a source of suffering and disability [4]. Common treatments to address such symptoms include rehabilitation programmes [6] and psychosocial interventions [7], however treatments can be resource intensive, such that novel, pragmatic, approaches are required.

Immersive virtual reality (VR) has been proposed as an adjunctive therapy for reducing cancer-related symptoms [8]. VR presents an interactive 3D human-computer interface that allows individuals to interact with and become immersed in a computer-generated environment in a naturalistic fashion [9]. Immersive VR uses a head-mounted display which blocks the participants’ view of the real world and often excludes sounds via noise-cancelling headphones, creating the illusion of being present in a virtual world [8, 9]. An example of an immersive VR application is ‘Snow World’ in which patients take a virtual journey down an icy river [10]. This application has been shown to effectively reduce pain in patients undergoing burn wound debridement [10]. VR has also been shown to decrease other physical symptoms such as vomiting and nausea [11], and even alter the perception of the length of one’s treatment [12]. In addition to physical symptoms, VR interventions effectively reduce psychological symptoms such as anxiety [11] and increase positive mood states and induce states of relaxation [13]. These beneficial effects have been demonstrated in a variety of clinical applications including during chemotherapy [11], painful procedures [14], and hospitalisation [13]. The effects do not appear to diminish with repeated use [15], meaning it can be used repeatedly throughout treatment. Thus, VR has been shown to effectively reduce certain symptoms in clinical contexts.

However, the literature so far is limited in several ways. First, studies have tended to focus on the ability of VR to reduce a single symptom such as pain or anxiety and ignored more holistic aspects of health status such as quality of life. Patients with MBC have marked impairments to quality of life [16] and it is important to consider such aspects of well-being in the assessment of interventions. Second, while pain has received considerable attention, other symptoms shown to impact this population have been relatively ignored. For example, fatigue is difficult to treat [17] and is rated by MBC patients as the symptom with the most impact on quality of life [18]. Apart from a single early study which found that the “Bedside Wellness System” VR application for cancer patients significantly decreased fatigue [19], no other studies have investigated the effect of VR on fatigue. Third, no studies of immersive VR for cancer patients have been conducted outside of a medical or laboratory environment. The focus on treatment-associated problems and the financial costs associated with VR mean that previous studies have been primarily hospital-based. However, the recent introduction of more affordable VR devices allows for home-based research where the patient may operate the intervention themselves [13]. The portability of such an intervention is also potentially of benefit to patients who face barriers accessing standard support services.

Finally, and arguably most importantly in the case of chronic disease, it has not been adequately established whether the benefits of VR can endure for longer timespans beyond usage of the device. There are anecdotal reports from chronic pain patients that analgesia following VR exposure can last for hours or days after the session ends [20], however, work with cancer patients have primarily focused on in-the-moment distraction of treatment [12] rather than determining whether positive benefits might be maintained. More systematic research is needed to establish whether anecdotal reports are accurate and translate to cancer contexts.

Here, we report a pilot study testing the efficacy and acceptability of a home-based immersive VR intervention to produce sustained improvements in quality of life and reductions in fatigue, pain, depression, and anxiety in patients with MBC. The primary aim of this pilot study was to establish whether VR should be pursued as a feasible and acceptable adjunctive therapy for producing enduring, clinically meaningful, alleviation of physical and psychological symptoms experienced by women with MBC.

Methods
Design
A mixed-methods, crossover design integrated pre-intervention, post-intervention, and 48-h follow-up
assessments of scores on outcome measures. Participants completed two different VR interventions, the order of which was counterbalanced and randomised between groups. The study was prospectively registered on the Australian New Zealand Clinical Trials Registry (ref: ACTRN12619001480178) and ethical approval was granted by the New Zealand Health and Disability Ethics Committee (ref: 19/NTB/146). All participants gave informed consent to participate.

Participants
Women with MBC were invited to participate through the mailing lists of Breast Cancer Foundation NZ (BCFNZ) and Sweet Louise (a charity support service for people with MBC). Given the exploratory nature of this study, a sample of 30 participants was determined as sufficient to assess the acceptability of a trial of this nature and to identify a large effect in outcomes. Participants were required to have a diagnosis of MBC, be over 18 years, be able to physically wear and tolerate the VR headset, and have experienced symptoms of fatigue, pain, or anxiety in the week prior to enrolment by study researchers. Participants were excluded if they had any visual, hearing, or cognitive impairments that would limit their ability to take part in the study, or if they could not read, speak, or write in English. Participants received NZ$100 for their participation.

VR intervention
All participants were provided with a Pico Goblin VR headset for use in their own homes. This included a 1280 × 1440 px LCD screen with a refresh rate of 70 Hz and a controller. Participants also received headphones (Panasonic RP-HT161), written instructions, and copies of the questionnaires. Two different VR interventions, “Happy Place” and “Ripple”, were used. Screen captures from each experience are provided in Fig. 1.

Fig. 1  Example Screen Captures from the Happy Place and Ripple VR Experiences. (A) a scene from the Happy Place VR experience. (B) the menu in the Ripple VR experience, where participants can choose between the river (left) beach (middle) or mountain (right) experiences
Happy Place [21], developed by Hjärtat in 2016, is a commercially available VR application in which participants experience a tranquil, animated camping scene. Participants experience changes to the weather and time of day and can interact with optional tasks, guided relaxation, and soothing music. Ripple is a collection of three short 360° VR nature scenes commissioned by BCFNZ and developed by Mixt Studio [22]. The three experiences are as follows: 1) a beach where the participant can write words in the sand or the sky; 2) a waterfall where the participant can stack stones; and 3) a mountain range where the participant can jump between different locations amongst mountaintops and lakes. The usability and acceptability of the Ripple VR experience in women with MBC had been found to be high in a previous proof-of-concept study.

**Outcome measures**
Participants completed questionnaires online at six different time points (See Fig. 2), each taking approximately 15–20 min to complete. Table 1 provides a summary of measures, the timing of application, and the minimum clinically important difference (MCID) as reported in the relevant literature.

Our primary outcome measure was quality of life as measured by the EQ-5D-5L [27]. The EQ-5D-5L asks...
participants to indicate their functioning in five areas—mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Participants rate themselves as having no problems, slight problems, moderate problems, severe problems, or extreme problems. The EQ-5D-5L has demonstrated good construct validity and reliability with cancer patients [23]. We used an online calculator (from euroqol.org) and UK values to calculate each participant’s index score. Participants also rate their quality of life on a visual analogue scale (VAS). In the current study, the index had an average Cronbach’s alpha across timepoints of 0.77 (SD = 0.08).

The Functional Assessment of Chronic Illness Therapy Fatigue scale (FACIT-Fatigue) [28] measures cancer-related fatigue. Participants rate how true items such as “I feel fatigued” have been over the last 7 days on a 5-point Likert scale from 0 (not at all) to 4 (very much) and scores are summed across the 13 items. Previous work has demonstrated the FACIT-Fatigue has good test-retest reliability, internal consistency, and concurrent validity in cancer patients [29]. The scale had good reliability in the current work across all timepoints (average Cronbach’s alpha = 0.90, SD = 0.03).

The Brief Pain Inventory – Short Form (BPI) includes 11 items used to assess pain. Participants rate the severity of their pain over the last 24 h and how it has interfered with things such as “enjoyment of life” on a scale from 0 (no pain/des not interfere) to 10 (pain as bad as you can imagine/interferes completely). Item scores are summed to create a total. The BPI has been shown to have excellent internal consistency among cancer patients [30] and was similarly observed in the current work with Cronbach’s alpha across timepoints of 0.94 (SD = 0.01).

The 21-item short version of the Depression, Anxiety, and Stress Scales (DASS-SF) [31] was used to measure depression, anxiety, and stress in our sample. The DASS-21 has been widely used in cancer patients and been shown to be valid and reliable [32]. This measure includes a subscale of 7 items for each construct. Participants rate the severity of negative emotions they experienced in the previous week on a scale of 0 (did not apply to me at all) to 3 (applied to me very much, or most of the time). Items are summed to create three separate scores for depression, anxiety, and stress. The depression subscale had an average reliability of 0.85 (SD = 0.07), anxiety was 0.51 (SD = 0.14), and the stress subscale average was 0.82 (SD = 0.05). Due to the low internal reliability of the anxiety scale, we removed one item (item 2, “mouth dryness”) as this is also a common side effect of chemotherapy and analgesic medicines prescribed in MBC. After removing this item, the average Cronbach’s alpha of the anxiety subscale improved to 0.65 (SD = 0.10).

Along with these questionnaires, the baseline (T1) questionnaire asked demographic and clinical questions. Finally, at the end of each intervention (T2 and T5), acceptability and satisfaction with the intervention were assessed by asking participants how likely they would be to use the intervention again (rated 0 to 100), and open-ended questions about what they liked and did not like about the interventions and suggestions for improvement.

**Procedure**

Participants were block randomised by age (<50 years vs. 50 years+) to order of the VR interventions. An independent researcher created and uploaded a randomisation table to REDCap. The study researchers were blinded to randomisation until after REDCap had allocated participants to group. Group 1 used Ripple before Happy Place (R:HP), and Group 2 experienced Happy Place before Ripple (HP:R). There was a one-week washout period to minimise carryover effects between the two interventions (see Fig. 2). During the intervention weeks, participants were instructed to use the VR experience...
every day for a minimum of 10 min. Participants kept a written log of the time spent using the headset to check adherence; these records were used to summarise participants’ engagement with VR.

**Statistical analyses**

We tested the normality of all continuous questionnaire data at each time point visually and with Shapiro-Wilk tests. The normality of quality of life measures (EQ-5D-5L index and VAS) were improved when squared, and the normality of the DASS measures (total, depression, anxiety, and stress) were improved with square-root transformation. The transformed data was therefore used for all analyses for these measures. To examine the effect of the VR interventions on our various outcome measures, linear mixed models were used, including fixed effects of VR experience (as per assigned group of Ripple or Happy Place), time point (pre, post, or follow-up), study period (first or second intervention received), and interaction terms of time point with each period and VR experience. The REML method was used with a random effect term included for participant and with an autoregressive correlation structure used for residuals. REML estimation was used for all models, since maximum likelihood estimation can produce biased estimates of covariance parameters [33, 34]. The Kenward and Roger adjustment was also used, which can control type I errors in smaller samples [35]. Results are reported using pairwise comparisons of estimated marginal mean differences between study time points (pre vs post, post vs follow-up, pre vs follow-up). Residuals from all models were evaluated for normality and constant variance. Statistical significance was defined using a p-value < 0.05. Analyses were performed using SPSS (version 26) or Stata (version 16). We first looked at the average decrease across interventions by using the difference between the raw pre-intervention scores (average of T1 and T4) and follow-up scores (average of T3 and T6). For quality of life, we compared pre-intervention scores to the post-intervention score (the average of T2 and T5) as this was not measured at follow-up. The raw (untransformed) mean differences were calculated to enable comparisons with MCIDs and assessed according to the conventions summarised in Table 1. Thematic analysis was used to analyse open-ended questions regarding intervention acceptability.

**Results**

Recruitment commenced in October 2019 and data collected until March 2020. Response to invitations exceeded expectations; 46 participants were initially assessed of whom 40 met the inclusion criteria (See Fig. 2 for the study flow diagram). Two participants were lost due to attrition over the course of the study, leaving a final sample size of 38. The remaining sample were primarily NZ European (81.6%, n=31) with low representation from other ethnicities (see Table 2). The sample was well-educated with many who had completed tertiary education (57.9%, n=22).

**Effect of VR on outcome measures**

The raw (untransformed) means for outcome measures at each time point are summarised in Table 3. A mixed model analysis showed that, overall, there was no main effect of VR experience and no interactions including VR experience; suggesting that Ripple and Happy Place experiences did not differ on any measure. This can be seen in Fig. 3, which shows the marginal means for each time point and VR experience separately, with very little difference between the two VR experiences. There were also no significant effects or interactions including study period.

However, there were significant main effects of time for both VR experiences on every outcome measure, comparing baseline measurements (pre) to those taken at the end of each week-long VR experience (post) and/or or 48 h later (follow-up). The estimated marginal mean pairwise comparisons for each time point are presented in detail in Table 4. There was a small but statistically significant increase in quality of life between pre- and post-intervention (note that quality of life was not measured at follow-up). Fatigue significantly decreased between the pre and post timepoints, and this was maintained at follow-up. BPI scores were lower post-intervention; however, this did not become statistically significant until follow-up. DASS Total, DASS Anxiety, and DASS Stress all decreased between pre and post, and these measures improved further and reached significance at follow-up. DASS depression also decreased between pre and post, but the further improvement at follow-up was not statistically significant.

Some of the changes over time met the published threshold for a clinically meaningful difference (MCID; Table 1). While quality of life improved by 0.06 points on the index, falling short of the MCID of 0.08 [23], the improvement of 6.78 points on the VAS was close to the clinically important difference of 7 [23]. Participants experienced an average decrease in fatigue of 5.00, larger than the MCID of 4 points [24]. The effect size (Cohen’s d) of the observed reduction in pain was 0.28. Since an effect size of $d=0.50$ is suggested as the cut-off for clinical importance [25], this result was not clinically significant. The observed average reduction in depression levels of 3.80 was smaller than the suggested MCID of 5.01 [26] but, of note, it brought the average score of our participants down into the ‘normal’ range (<9.03). The change...
in anxiety of −1.89 was not deemed clinically important compared to the suggested MCID of 5.38 [26]. Finally, the observed reduction in stress scores of 3.13 was also smaller than the MCID of 4.90 [26], but again this brought our sample to within the normal range (<12.27).

Analysis from linear mixed models (fixed effects: group, VR experience; random effect: participant) of each outcome measure at the two baselines (T1 and T4) indicated no evidence of carry-over effects, with no statistically significant interactions between period and group. Despite the successful washout period, it was clear that there were larger decreases in the outcome measures across the entire study period than across any 1 week of the study (Table 3). We therefore also looked at the change in outcome measures across the entire study period by using the difference between T1 and T6 scores (T1 and T5 for quality of life). The change in quality of life across the entire study period was 0.10 on the index, now greater than the suggested cut-off of 0.08. The change of 4.09 on the VAS did not meet the cut-off of 7. Fatigue decreased by 7.94 points overall, again larger than the MCID of 4 points. The effect size for the decrease in pain

### Table 2  Demographic Characteristics of the Sample

| Measure                          | Mean (SD) or N (%)               |
|---------------------------------|----------------------------------|
| Age                             | All Participants (N = 38)        |
|                                 | R:HP (n = 20)                    |
|                                 | HP-R (n = 18)                    |
|                                 | Age Years; mean (SD)             | 52.03 (11.40) | 52.70 (13.20) | 51.28 (9.32) |
|                                 | Ethnicity                       |                          |
|                                 | NZ European                     | 31 (81.6%)              | 15 (75%)      | 16 (89%)      |
|                                 | NZ Maori                        | 1 (2.6%)                | 0 (0%)        | 1 (5.6%)      |
|                                 | NZ Maori/European               | 5 (13.2%)               | 5 (25%)       | 0 (0%)        |
|                                 | Pacific                         | 1 (2.6%)                | 0 (0%)        | 1 (5.6%)      |
|                                 | Highest education               |                          |
|                                 | Secondary                       | 16 (42.1%)              | 12 (60%)      | 4 (21%)       |
|                                 | Tertiary                        | 15 (39.5%)              | 6 (30%)       | 9 (52.6%)     |
|                                 | Post-graduate                   | 7 (18.4%)               | 2 (10%)       | 5 (26.3%)     |
|                                 | Employment status               |                          |
|                                 | Full-time                       | 10 (26.3%)              | 4 (20%)       | 6 (36%)       |
|                                 | Part-time                       | 7 (18.4%)               | 5 (25%)       | 2 (11%)       |
|                                 | Not working                     | 21 (55.3%)              | 11 (55%)      | 10 (55.6%)    |
|                                 | Relationship status             |                          |
|                                 | Single                          | 7 (18.4%)               | 3 (15%)       | 4 (22%)       |
|                                 | Divorced/separated/widowed      | 9 (23.7%)               | 4 (20%)       | 5 (28%)       |
|                                 | Married/cohabitating            | 22 (57.9%)              | 13 (65%)      | 9 (50%)       |
|                                 | Cancer treatment                |                          |
|                                 | Chemotherapy only               | 8 (21.1%)               | 5 (25%)       | 3 (16.7%)     |
|                                 | Hormone therapy only            | 16 (42.1%)              | 8 (40%)       | 8 (44.4%)     |
|                                 | Hormone and target therapy      | 8 (21.1%)               | 4 (20%)       | 4 (22.2%)     |
|                                 | Radiation and hormone therapy   | 1 (2.6%)                | 1 (5%)        | 0 (0%)        |
|                                 | No current medical cancer treatment | 5 (13.2%)           | 2 (10%)       | 3 (16.7%)     |
|                                 | Time since diagnosis            |                          |
|                                 | Years; mean (SD)                | 7.16 (7.18)             | 7.15 (7.74)   | 7.17 (6.72)   |

### Table 3  Descriptive Statistics of Raw Outcome Measures at Each Time Point

| Measure              | T1 (day 0) | T2 (day 7) | T3 (day 9) | T4 (day 15) | T5 (day 21) | T6 (day 23) |
|----------------------|------------|------------|------------|-------------|-------------|-------------|
| EQ-Index             | 0.64 (0.21)| 0.69 (0.17)| –          | 0.67 (0.21) | 0.74 (0.11) | –           |
| EQ-VAS               | 61.16 (21.55) | 68.90 (15.24) | –          | 60.03 (22.96) | 65.25 (23.51) | –           |
| FACIT-Fatigue        | 22.41 (8.78) | 17.03 (7.27) | 16.52 (9.22) | 18.55 (9.68) | 15.48 (7.61) | 14.47 (10.24) |
| BPI                  | 38.61 (21.23) | 39.50 (19.93) | 35.51 (21.80) | 39.50 (21.67) | 34.25 (18.31) | 30.48 (19.36) |
| DASS Total           | 33.05 (23.60) | 23.42 (13.19) | 20.11 (13.51) | 20.69 (11.17) | 20.31 (14.62) | 15.94 (10.42) |
| DASS Depression      | 12.95 (11.08) | 7.05 (5.73) | 7.19 (6.71) | 6.97 (5.12) | 7.19 (6.52) | 5.18 (5.02) |
| DASS Anxiety         | 5.11 (5.95) | 3.63 (3.48) | 2.49 (3.31) | 3.14 (3.12) | 3.25 (3.89) | 2.12 (2.78) |
| DASS Stress          | 12.84 (8.46) | 10.84 (6.34) | 8.60 (5.56) | 8.80 (5.14) | 8.00 (6.08) | 6.94 (5.29) |
across the entire study period was $d = 0.40$ – an improvement but still short of the suggested clinically important effect size of $d = 0.50$. The gross reductions in depression (7.77) and stress (5.90) easily reached the MCID level, but the reduction in anxiety (2.99), again, did not.

**Engagement**

Log books were used to record daily VR usage during the intervention weeks, with data available for 34 (89.5%) participants during the first intervention week and 31 (81.5%) during the second intervention week. Log books could not be retrieved from some participants ($n = 4$ week 1, $n = 7$ week 2), who were all in group 2 (HP:R). Where this information was available, VR usage was consistently high, with an average of 6.6 days ($SD = 1.1$, range 1–7) of VR usage recorded during each 7-day intervention week. Despite being instructed to use the VR experiences for approximately 10 min per day, the average daily duration was 12.8 min ($SD = 5.0$ min, range 6.57–35.14) and the mean number of VR usage minutes per week was 95.7 min ($SD = 33.3$ min, range 30–246). There was no difference in the duration of VR usage between the two groups in either the first (mean difference: $-2.33$, 95% CI: $-5.33$ to $0.67$, $t(32) = 1.58$, $p = 0.124$) or second (mean difference: $0.98$, 95% CI: $-3.47$ to $5.42$, $p = 0.656$) study period.

**Acceptability**

The acceptability of the interventions was high. Participants reported high likelihood of using the VR interventions again and mean ratings were similar across experiences (Mean scores: Happy Place = 73.01; Ripple = 66.67). Participant comments indicated that participants perceived the experiences to have provided benefit:

“Since starting the experiment I have had more energy, lasted full days at work, could still function when I got home, my memory is better ... it’s the best I’ve felt since before starting treatment.”
Table 4  Comparison of outcome measurements across all available time points, from linear mixed models

| Measure                  | Comparison       | Estimated marginal mean difference | 95% CI       | p-value | Raw mean difference (SD) |
|--------------------------|------------------|-----------------------------------|--------------|---------|-------------------------|
| EQ-SD-SL(SD)             | Post vs Pre      | 0.06                              | [0.03, 0.09] | < 0.001 | 0.06 (0.13)             |
| FACIT-Fatigue            | Post vs Pre      | 724.65                            | [21.04, 1428.25] | 0.044 | 6.78 (26.17)             |
| BPI                      | Post vs Pre      | −3.94                             | [−5.83, −2.05] | < 0.001 | −3.88 (7.49)             |
|                          | Follow-up vs Pre | −5.00                             | [−7.03, −2.98] | < 0.001 | −5.00 (9.10)             |
|                          | Follow-up vs Post| −1.07                             | [−2.97, 2.83]  | 0.272  | −1.15 (7.34)             |
| DASS Total               | Post vs Pre      | −2.17                             | [−5.77, 1.43]  | 0.236  | −2.07 (15.03)            |
|                          | Follow-up vs Pre | −6.01                             | [−10.13, −1.90] | 0.004 | −5.66 (19.89)            |
|                          | Follow-up vs Post| −3.84                             | [−7.46, −0.22] | 0.038  | −4.30 (15.49)            |
| DASS Depression          | Post vs Pre      | −0.42                             | [−0.73, −0.11] | 0.008  | −0.54 (17.05)            |
|                          | Follow-up vs Pre | −0.92                             | [−1.27, −0.57] | < 0.001 | −0.88 (15.41)            |
|                          | Follow-up vs Post| −0.5                              | [−0.81, −0.19] | 0.002  | −0.41 (10.46)            |
| DASS Anxiety             | Post vs Pre      | −0.48                             | [−0.71, −0.24] | < 0.001 | −0.30 (7.58)             |
|                          | Follow-up vs Pre | −0.69                             | [−0.96, −0.43] | < 0.001 | −0.39 (7.03)             |
|                          | Follow-up vs Post| −0.22                             | [−0.46, 0.02]  | 0.077  | −1.01 (4.17)             |
| DASS Stress              | Post vs Pre      | −0.13                             | [−0.39, 0.13]  | 0.320  | −0.66 (4.33)             |
|                          | Follow-up vs Pre | −0.55                             | [−0.82, −0.28] | < 0.001 | −1.80 (4.10)             |
|                          | Follow-up vs Post| −0.42                             | [−0.68, −0.16] | 0.001  | −1.22 (3.16)             |
|                          | Follow-up vs Pre | −0.19                             | [−0.43, 0.05]  | 0.117  | −1.37 (6.92)             |
|                          | Follow-up vs Post| −0.55                             | [−0.82, −0.29] | < 0.001 | −3.07 (6.49)             |
|                          | Follow-up vs Post| −0.36                             | [−0.60, −0.12] | 0.003  | −1.77 (5.37)             |

* scores analysed using squared transformation  
** scores analysed using square root transformation  

"With my lack of mobility that’s resulted from my illness, I really enjoyed the VR as it made me feel like I’m not house bound... I could immerse myself elsewhere and it helped take the focus off my pain."

However, some participants reported adverse effects in using the VR headsets including feeling “claustrophobic" and “the first time I used it, I looked at a lot of things (the interactive things) and I got a bit dizzy/nauseous.”

Feedback about specific aspects participants ‘liked’ and ‘did not like’ regarding the VR experiences fell within two key themes: 1) relaxation was helpful, and 2) it was enjoyable to spend time in nature. Theme one reflects the benefits gained from engaging in a relaxation experience. Happy Place was described as “very similar to meditation methods” and Ripple was “very relaxing … I found it much easier to get to sleep after using it” and “it made me stop in the day and let my mind be a lot more calm and still than it usually is”. Key suggestions for improvement centred on inducing relaxation more effectively by keeping the experiences simple and slow paced. Examples of participant’s comments in this regard are “[there were] too many things to interact with [and it was] sometimes hard to relax”, “it changed from day to night (and vice versa) too quickly”, and “the image cycle was too short.”

The second theme reflects how participants enjoyed connecting with the nature settings because a) it reminded them of their childhood “loved camping … brought back things I did as a kid … sitting by fire … it was truly beautiful” (Happy Place), and b) it connected them with the tangible aspects of nature, “feels like I’m inhaling pure freshness and the sound and atmosphere makes it feel so real” and “especially the beach … I looked forward to the time when I could chill out, felt like I was there and I loved it” (Ripple). Connection with nature was reinforced by feedback suggesting a preference for the real nature footage of Ripple compared to the “cartoonish” and unrealistic graphics of Happy Place. Another person noted that “some of the scenes made me feel a little isolated” (Ripple) which suggests there is a balance between quiet space and feeling alone and that some interactivity can counter feelings of isolation.

Discussion
This pilot study tested the efficacy and acceptability of an immersive VR experience used at-home by patients with MBC. Although there were no differences between
Interventions, scores on quality of life, fatigue, pain, depression, anxiety, and stress all improved over time between baseline and post-intervention and/or follow-up timepoints. Scores for fatigue, arguably the most important symptom [18], easily met the level considered clinically important at intervention follow-up and across the entire study period. Improvements also met the level considered clinically important across the entire study period for quality of life, depression, and stress. Depression and stress levels dropped below the clinical cut-offs after the intervention. Taken together, the results from this pilot study suggest that immersive VR can be an effective therapy for the physical and psychological symptoms of MBC and warrant further exploration in a full randomized controlled trial. This study aimed to address four key gaps in the VR research to date and these are discussed below.

First, our study demonstrated quality of life improvements via VR usage. Fifty-nine percent of surveyed women with MBC in New Zealand state that the symptoms and side-effects of their treatment negatively impact their quality of life, and only one-third feel that they have a good level of control over their symptoms [36]. We have shown that a self-reported increase in quality of life occurred alongside a decrease in the severity of symptoms such as fatigue, pain, depression, anxiety, and stress. Interestingly, only 6% of oncology therapies recently approved by the FDA were able to report a clinically important increase in quality of life [37]. Other research suggests there may be important flow on effects from increased quality of life including improved immune functioning from reduced stress and depression [9] and increased adherence to treatment due to better symptom management [11, 38]. Lower anxiety and fatigue also predict longer recurrence-free times and longer overall survival in early breast cancer [39]. Thus, our preliminary findings suggest that using VR to reduce symptoms and side-effects in patients with MBC has the potential to improve quality of life.

Second, we have demonstrated that the established benefits of VR on symptoms of pain, depression, and anxiety, also extend to fatigue. In fact, the decrease in fatigue was one of the more robust findings; this was clinically important across the average of the one-week interventions as well as across the entire three-week study period. Fatigue is rated the most important symptom by advanced cancer patients [18]. The prevalence of “severe” fatigue in patients with advanced cancer is likely to range from 60 to 90% [17, 36] and often co-occurs with pain [17]. Fatigue in cancer survivors is also associated with higher levels of pro-inflammatory cytokines [40] and chronic inflammation [41], creating an environment which promotes tumour growth [42]. Including fatigue as a measure gives us a greater understanding of how VR can improve the lives of patients with MBC in a way that is truly meaningful to them.

Third, our findings demonstrate that an at-home, patient-operated, VR intervention can be a viable and acceptable treatment for MBC patients. While the effects of VR during treatments or hospitalization had been studied, there had been no previous work investigating whether patients with MBC could use VR to deal with the day-to-day occurrence of side effects in their own homes. Accessible treatments are vital in a healthcare system where access to treatment varies dramatically between regions and regional patients must travel long distances for treatment [36]. People who live in a town or city without a tertiary cancer treatment centre typically have fewer treatment and support options and are less likely to participate in clinical trials [36]. Additionally, 15.8% of our sample were Māori women, who face disproportionately high rates of MBC diagnoses and low survival rates through restricted access to treatment [36]. Since the study was completed, the Covid-19 pandemic has further restricted healthcare and travel options for these patients, making home-based interventions even more essential. The observed effects from this at-home intervention also counter the theory that VR interventions work by removing the individual from anxiety provoking environments [15]. Previous VR studies took place in hospitals, where the surrounding environment can exacerbate anxiety and other symptoms [15]. That these effects translated to a location where participants should presumably be more relaxed suggests that virtually removing someone from an anxiety provoking situation is not the only mechanism by which VR exerts its influence.

Finally, our findings indicate the duration of beneficial effects. While there has been some work demonstrating maintenance of effects over time, this has not been well-established. One study noted that using VR during chemotherapy could reduce instances of vomiting and fatigue for up to 3 days [19], and another pilot study reported effects from 2 to 48 h after the VR intervention [20]. Other studies have provided anecdotal evidence [11] or non-significant trends [43] suggesting an extended analgesic effect. We have demonstrated that the effect of VR across multiple measures was either maintained at 48-h follow-up (in the case of fatigue and depression) or had improved further (pain, anxiety, and stress). This has implications for another of the primary cognitive explanations of how VR exerts its effect – through distraction. Immersive VR is engaging and may divert the patient’s attentional resources from focusing on pain or rumination to more helpful endeavors [11]. However, presumably this distraction effect would not occur in the days after removal of the headsets and so cannot fully explain
maintenance of VR effects. Our findings suggest that the positive effects of VR interventions can be sustained for at least 48h post-intervention, beyond the point at which distraction effects would have worn off.

Limitations and next steps
Although this work has several strengths and extends the literature on the use of VR interventions by people with MBC, it is not without limitations. The most important issue requiring consideration is the lack of a control group which limits our ability to claim causation of effects. However, this pilot study has demonstrated beneficial effects over time and provides evidence that a follow-up randomized controlled trial is feasible, valuable, and necessary. The feedback to the open-ended questions demonstrates acceptability and informs development of future VR experiences for further research. We are also unable to quantify how much, if any, additional benefit VR may provide MBC patients over typical pain or anti-depressant medication, or alternative psychological interventions such as hypnosis, image therapy, or standard meditation and mindfulness practice. Further studies should investigate these possibilities.

Another suggestion for further studies is considering lengthening the duration of exposure to VR experiences. While most of our measures showed clinically important differences across time, this was not always the case. This may suggest that a single week of VR was not sufficient to produce clinically important improvements in some metrics, despite clearly producing statistically significant improvements. This finding fits with previous work suggesting the effects of VR do not diminish with repeated use [15] and indicates that there may be a dose-response relationship where participants gain greater benefit with increased exposure. Further studies should also consider that some people may find wearing VR headsets uncomfortable or disorienting and factor this possibility in to the development of interventions.

Furthermore, the observed reductions in anxiety did not meet the threshold for a clinically important decrease. One reason for this may be that our sample reported relatively low anxiety from the outset; the mean DASS Anxiety score of 5.11 at baseline was already well within the “normal” range (< 6.27). This may have created a floor effect in which anxiety could not have been further reduced by the intervention. The DASS anxiety subscale also displayed poor internal reliability in our sample, even after the removal of one item related to cancer treatment. Recruiting participants with high baseline anxiety for future studies would enable investigation in a group that, arguably, are in need of such an intervention.

Finally, to minimize participant burden, we did not include the quality of life measure at the 48-h follow-up. While we know that scores on all other measures improved at this time point, we are unable to comment on whether quality of life improvements were also sustained. Future studies should measure quality of life over time to see whether clinically important improvements are maintained. Another important extension would be to look for downstream effects on treatment adherence that come from being better able to tolerate the side-effects of treatment. Similarly, measuring physiological or biological outcomes could reveal a link between the effects of VR on fatigue, pain, and mood, and potentially health outcomes and survival rates—for example, an associated decrease in cortisol levels or inflammation would suggest that such VR interventions might even improve immune function and responses to treatment [42, 44] and would provide objective outcome measures rather than the self-report measures we have used.

Conclusions
This pilot study has shown that immersive VR interventions have the potential to produce meaningful and sustained reductions in symptoms of fatigue and improve quality of life in women with MBC. Importantly, positive results were sustained for at least 2 days after people stopped using the VR headsets. Furthermore, this work indicates using a VR intervention in a patient’s own home is acceptable to patients. Our results suggest opportunities for future studies with longer duration and a wider range of outcomes including objective biometric measures.

Abbreviations
BPI: Brief Pain Inventory – Short Form; BCFNZ: Breast Cancer Foundation NZ; DASS: Depression, Anxiety, and Stress Scales; FACIT: Functional Assessment of Chronic Illness Therapy; FDA: Food and Drug Administration; LCD: Liquid Crystal Display; MBC: Metastatic breast cancer; MCID: Minimum clinically important difference; REML: Restricted maximum likelihood; VR: Virtual reality.

Acknowledgements
Not applicable.

Authors’ contributions
Study conception and design: LR, AC, AA, GT, RD and AG; Acquisition of data: SC and AA; Analysis and interpretation of data: LR, AC, SC, and AA; Writing manuscript: LR, AC, SC, ZL, AA, RB and AG. All authors have read and approved the final manuscript.

Funding
This work was funded by grant #3719356 from BCFNZ.

Availability of data and materials
The dataset used and analysed during the current study are available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
Ethics approval was obtained from Health and Disability Ethics Committee (ref: 19/NNT/146). Informed consent was obtained in writing from participants and all procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.

Consent for publication
Not applicable.

Competing interests
AG is employed by the funder of this study (BCFNZ) who also commissioned the development of one of the VR interventions tested in this work (Ripple). No other authors have no competing interests.

Author details
1 Department of Psychological Medicine, The University of Auckland, Auckland, New Zealand. 2 Section of Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand. 3 School of Psychology, Victoria University of Wellington, Wellington, New Zealand. 4 National Institute for Health Innovation, The University of Auckland, Auckland, New Zealand. 5 Medical Oncology Department, Auckland City Hospital, Auckland, New Zealand. 6 Breast Cancer Foundation NZ, Auckland, New Zealand.

Received: 27 August 2021 Accepted: 25 November 2021
Published online: 02 April 2022

References

1. Seneviratne S, Lawrenson R, Harvey V, Ramsarop R, Elwood M, Scott N, et al. Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology. BMC Cancer. 2016;16(1):1–9.
2. Mosher CE, Daily S, Tometich D, Matthias MS, Outcalt SD, Hirsh A, et al. Factors underlying metastatic breast cancer patients’ perceptions of symptom importance: a qualitative analysis. Eur J Cancer Care. 2018;27(1):e12540.
3. Niklasson A, Paty J, Rydén A. Talking about breast cancer: which symptoms and treatment side effects are important to patients with advanced disease? Patient - Patient-Centered Outcomes Res. 2017;10(6):719–27.
4. Cleeland C, von Moos R, Walker MS, Wang Y, Gao J, Chavez-MacGregor M, et al. Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. Support Care Cancer. 2016;24(8):3557–65.
5. Park EM, Gelber S, Rosenberg SM, Seah DSE, Schapira L, Come SE, et al. Anxiety and depression in young women with metastatic breast cancer: a cross-sectional study. Psychosomatics. 2018;59(3):251–8.
6. Paolucci T, Saggino A, Agostini F, Paoloni M, Bernetti A, Mangone M, et al. The influence of rehabilitation on quality of life in breast cancer survivors: a clinical study. Int J Environ Res Public Health. 2021;18(16):8585.
7. Teo I, Krishnan A, Lee GL. Psychosocial interventions for advanced cancer patients: a systematic review. Psycho-Oncology. 2019;28(7):1394–407.
8. Cicchetti A, Lucidi F, De Laurentiis M, Milanesi C, Napolì A, Giordano A. Virtual reality in health system: beyond entertainment. A Mini-review on the efficacy of VR during Cancer treatment. J Cell Physiol. 2016;231(2):275–87.
9. Ventura S, Bahos RM, Botella C. Virtual and augmented reality: new Frontiers for clinical psychology. In: State of the Art Virtual Reality and Augmented Reality Knowhow. ThroughTech, 2018 [cited 2019 May 23]. Available from: http://www.intechopen.com/books/state-of-the-art-virtuaal-reality-and-augmented-reality-knowhow/virtual-and-augmented-reality-new-frontiers-for-clinical-psychology.
10. Hoffman HG, Patterson DR, Seibel E, Soltani M, Jewett-Leahy L, Sharar SR. Virtual reality pain control during burn wound debridement in the hydrotank. Clin J Pain. 2008;24(4):299–304.
11. Schneider SM, Prince-Paul M, Allen MJ, Silverman P, Talaba D. Virtual reality as a distraction intervention for women receiving chemotherapy. Oncol Nurs Forum. 2004;31(1):81–8.
12. Schneider SM, Kibsy CK, Flint EP. Effect of virtual reality on time perception in patients receiving chemotherapy. Support Care Cancer. 2011;19(4):555–64.
13. Bahos RM, Espinoza M, García-Palacios A, Cervera JM, Esquerdo G, Barrajón E, et al. A positive psychological intervention using virtual reality for patients with advanced cancer in a hospital setting: a pilot study to assess feasibility. Support Care Cancer. 2013;21(1):263–70.
14. Gerçekeş Ö, Bektaş M, Aydınok Y, Oren H, Ellidokuz H, Olgun N. The effect of virtual reality on pain, fear, and anxiety during access of a port with huber needle in pediatric hematology-oncology patients: randomized controlled trial. Eur J Oncol Nurs. 2021;50:101886.
15. Hoffman H, Patterson D, Carrougher G, Sharar S. Effectiveness of virtual reality–based pain control With multiple treatments. Vol. 17, The Clinical Journal of Pain. 2001. p. 229–35.
16. Reed E, Simmonds P, Haviland J, Corner J. Quality of life and experience of Care in Women with Metastatic Breast Cancer: a cross-sectional survey. J Pain Symptom Manag. 2012;43(4):747–58.
17. Bardwell WA, Ancoli-Israel S. Breast Cancer and fatigue. Sleep Med Clin. 2008;3(1):61–71.
18. Butt Z, Rosenbloom SK, Abernethy AP, Beaumont JL, Paul D, Hampton D, et al. Fatigue is the Most important symptom for advanced Cancer patients who have had chemotherapy. J Natl Compr Cancer Netw. 2008;6(5):448–55.
19. Oyama H, Kameda M, Katsumura N, Akechi T, Ohshima M. Using the bedside wellness system during chemotherapy decreases fatigue and emesis in cancer patients. J Med Syst. 2000;24(3):173–82.
20. Melville NA. Virtual reality ventures into real world of chronic pain. Medscape. 2016.
21. Hjartå T. Happy Place VR. Wenderfalck. 2016 [cited 2021 Aug 24]. Available from: https://wenderfalck.com/projects/happy-place-vr.
22. Mixt Studio. Ripple VR Experience. 2016 [cited 2021 Aug 24]. Available from: https://mixstudio.co.nz/work/ripple-vr-experience.
23. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-SD utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5(1):1–8.
24. Yost KI, Eton DT. Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences: The FACIT Experience. http://dx.doi.org/epoxy.auckland.ac.nz/101177/16132787/075273540. 2016;28(2):172–91.
25. Wong K, Zeng L, Zhang L, Bedard G, Wong E, Tsao M, et al. Minimal clinically important differences in the brief pain inventory in patients with bone metastases. Support Care Cancer. 2013;21(7):1893–9.
26. Ronk PR, Korman JR, Hooke GR, Page AC. Assessing clinical significance of treatment outcomes using the dass-21. Psychol Assess. 2013;25(4):1103–10.
27. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-SD (EQ-SD-5L). Qual Life Res. 2011;20(10):1727–36.
28. Cella DF, Lai JS, Chang CH, Petersen A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):502–12.
29. Eden MM, Kunkel K. Psychometric properties of the modified brief fatigue inventory and FACIT-fatigue in individuals with cancer of the head and neck. Rehabil Oncol. 2016;34(3):97–103.
30. Shin H, Kim K, Young Hee Kim, Chee W, Im EO. A comparison of two pain measures for Asian American cancer patients. West J Nurs Res. 2008;30:181–96.
31. Lovibond P, Lovibond S. The structure of negative emotional states: comparison of the depression anxiety stress scales (DASS) with the Beck depression and anxiety inventories. Behav Res Ther. 1995;33(3):335–43.
32. Fox RS, Lillis TA, Gerhart J, Hoeger M, Duberstein P. Multiple group confirmatory factor analysis of the DASS-21 depression and anxiety scales: how do they perform in a cancer sample? Psychol Rep. 2018;121(3):548–65.
33. Swallow WH, Monahan JF. Monte carlo comparison of ANOVA, MIVQUE, REML, and ML estimators of variance components. Technometrics. 1984;26(1):47–57.
34. Harville DA. Maximum likelihood approaches to variance com-ponent estimation and to related problems. J Am Stat Assoc. 1977;72(358):320–38.
35. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53(3):983.
36. Gautier A. “I’m still here”: insights into living - and dying - with advanced breast cancer in New Zealand. Breast. 2019;48:569–70.
37. Arciero V, Santos SD, Koshy L, Rahmadian A, Saluja R, Everest L, et al. Assessment of Food and Drug Administration– and European medicines agency–approved systemic oncology therapies and clinically meaningful improvements in quality of life: a systematic review. JAMA Netw Open. 2021;4(2):e2033004–4.
38. Tanja-Dijkstra K, Pahl S, White MP, Andrade J, Qian C, Bruce M, et al. Improving dental experiences by using virtual reality distraction: a simulation study. PLoS One. 2014;9(3):e91276.
39. Wender R, Hoffman HG, Hunner HH, Seibel EJ, Patterson DR, Sharar SR. Interactivity influences the magnitude of virtual reality analgesia. J Cyber Ther Rehabil. 2009;2(1):27–33.
40. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64(4):604–11.
41. Bower JE, Ganz PA, Aziz N, Fahey JL, Cole SW. T-cell homeostasis in breast cancer survivors with persistent fatigue. JNCI J Natl Cancer Inst. 2003;95(15):1166–8.
42. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and Cancer. Cell. 2010;140(6):883–99.
43. Jones T, Moore T, Choo J. The impact of virtual reality on chronic pain. PLoS One. 2016;11(12):e0167523.
44. Gany L, Hersant B, Sidahmed-Mezi M, Dhonneur G, Meningaud JP. Using virtual reality to control preoperative anxiety in ambulatory surgery patients: a pilot study in maxillofacial and plastic surgery. J Stomatol Oral Maxillofac Surg. 2018;119(4):257–61.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.